ABS-1230 for Epilepsy

(KYRON Trial)

This trial tests a new treatment called ABS-1230 to determine its safety and effectiveness for people with KCNT1-related epilepsy, a condition causing frequent motor seizures. Participants will receive either ABS-1230 or a placebo (a substance with no active treatment) to compare effects. It is suitable for individuals diagnosed with KCNT1-related epilepsy who experience at least four motor seizures per week. Participants should not take certain medications and must maintain stable epilepsy medications during the trial.

As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to important advancements in epilepsy care.

You can continue taking your current antiseizure medications as long as you are not taking more than six and can keep the doses stable. However, you cannot take phenytoin, carbamazepine, stiripentol, or quinidine.

Research has shown that ABS-1230 has undergone safety testing in healthy volunteers. In these past studies, participants tolerated all doses well, experiencing no serious side effects. This finding reassures those considering joining the trial, as it indicates the treatment has been relatively safe in early testing.

The medicine specifically targets the genetic changes causing seizures in people with KCNT1-related epilepsy, making ABS-1230 a promising option for addressing the root cause of the problem.

Unlike standard epilepsy treatments like antiepileptic drugs, which often work by stabilizing electrical activity in the brain, ABS-1230 is unique because it targets a novel pathway that may more effectively control seizures. Researchers are excited about ABS-1230 due to its potential to provide relief for patients who do not respond well to existing medications. Additionally, the different parts of the study, including the placebo comparison, highlight its distinctiveness in terms of understanding its effectiveness and safety comprehensively.

Research has shown that ABS-1230 might help treat KCNT1-related epilepsy. Early studies in mice found that this treatment can greatly reduce seizures by targeting changes in the KCNT1 gene. The results suggest that higher doses of ABS-1230 lead to fewer seizures. This treatment is specifically designed to help people with this type of epilepsy. Although information from human studies remains limited, these early results are promising. Participants in this trial will receive ABS-1230 at different stages to evaluate its effectiveness and safety.¹²⁵⁶⁷